Drug Trial Radar · NCT06997627
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 5, 2025
Primary completion
May 2026
Study completion May 2026
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
Conditions
- Tetanus-diphtheria-acellular Pertussis (Tdap)
Interventions
GC3111BBiological
0.5 mL, Intramuscular injection
Boostrix®Biological
0.5 mL, Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Solicited adverse events occurring by day 14 after administration of the investigational productTime frame: 14 days after administration of the IP
- Unsolicited adverse events occurring by day 28 after administration of the investigational productTime frame: 28 days after administration of the IP
- Acute adverse events occurring within 30 minutes after administration of the investigational productTime frame: 30 minutes after administration of the IP
- Serious adverse events (SAE) and adverse events of special interest (AESI) occurring up to 180 days after administration of the investigational productTime frame: 180 days after administration of the IP
- Clinically significant findings in vital signs, laboratory tests, 12-lead electrocardiograms, and physical examinationsTime frame: 28 days after administration of the IP
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.